392 related articles for article (PubMed ID: 16990605)
1. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
Astermark J; Donfield SM; DiMichele DM; Gringeri A; Gilbert SA; Waters J; Berntorp E;
Blood; 2007 Jan; 109(2):546-51. PubMed ID: 16990605
[TBL] [Abstract][Full Text] [Related]
2. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
Steen Carlsson K; Astermark J; Donfield S; Berntorp E
Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic decision-making in inhibitor patients.
Allen G; Aledort L
Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965
[TBL] [Abstract][Full Text] [Related]
4. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor.
Hayashi T; Tanaka I; Shima M; Yoshida K; Fukuda K; Sakurai Y; Matsumoto T; Giddings JC; Yoshioka A
Haemophilia; 2004 Jul; 10(4):397-400. PubMed ID: 15230956
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.
Zhou ZY; Hay JW
Clin Ther; 2012 Feb; 34(2):434-45. PubMed ID: 22285208
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF
Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
[TBL] [Abstract][Full Text] [Related]
7. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
8. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.
Tjønnfjord GE; Holme PA
Vasc Health Risk Manag; 2007; 3(4):527-31. PubMed ID: 17969383
[TBL] [Abstract][Full Text] [Related]
9. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors.
Gomperts ED; Astermark J; Gringeri A; Teitel J
Blood Rev; 2008 Feb; 22 Suppl 1():S1-11. PubMed ID: 18485996
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
[TBL] [Abstract][Full Text] [Related]
11. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
[TBL] [Abstract][Full Text] [Related]
12. FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry.
Borg JY; Négrier C; Durieu I; Dolimier E; Masquelier AM; Lévesque H;
Haemophilia; 2015 May; 21(3):330-337. PubMed ID: 25359571
[TBL] [Abstract][Full Text] [Related]
13. Current opinion on inhibitor treatment options.
Mathew P
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374
[TBL] [Abstract][Full Text] [Related]
14. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.
Furukawa S; Nogami K; Ogiwara K; Yada K; Minami H; Shima M
J Thromb Haemost; 2015 Jul; 13(7):1279-84. PubMed ID: 25903848
[TBL] [Abstract][Full Text] [Related]
15. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
Franchini M; Coppola A; Tagliaferri A; Lippi G
Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
[TBL] [Abstract][Full Text] [Related]
16. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice.
Holmberg HL; Lauritzen B; Tranholm M; Ezban M
J Thromb Haemost; 2009 Sep; 7(9):1517-22. PubMed ID: 19566792
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis in haemophilia with inhibitors: update from international experience.
Carcao M; Lambert T
Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
[TBL] [Abstract][Full Text] [Related]
18. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.
Holme PA; Glomstein A; Grønhaug S; Tjønnfjord GE
Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748
[TBL] [Abstract][Full Text] [Related]
19. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
Holme PA; Brosstad F; Tjønnfjord GE
Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
[TBL] [Abstract][Full Text] [Related]
20. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
